Literature DB >> 17978177

Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.

Louise J Young1, Nicholas S Wilson, Petra Schnorrer, Adele Mount, Rachel J Lundie, Nicole L La Gruta, Brendan S Crabb, Gabrielle T Belz, William R Heath, Jose A Villadangos.   

Abstract

When dendritic cells (DCs) encounter signals associated with infection or inflammation, they become activated and undergo maturation. Mature DCs are very efficient at presenting antigens captured in association with their activating signal but fail to present subsequently encountered antigens, at least in vitro. Such impairment of MHC class II (MHC II) antigen presentation has generally been thought to be a consequence of down-regulation of endocytosis, so it might be expected that antigens synthesized by the DCs themselves (for instance, viral antigens) would still be presented by mature DCs. Here, we show that DCs matured in vivo could still capture and process soluble antigens, but were unable to present peptides derived from these antigens. Furthermore, presentation of viral antigens synthesized by the DCs themselves was also severely impaired. Indeed, i.v. injection of pathogen mimics, which caused systemic DC activation in vivo, impaired the induction of CD4 T cell responses against subsequently encountered protein antigens. This immunosuppressed state could be reversed by adoptive transfer of DCs loaded exogenously with antigens, demonstrating that impairment of CD4 T cell responses was due to lack of antigen presentation rather than to overt suppression of T cell activation. The biochemical mechanism underlying this phenomenon was the down-regulation of MHC II-peptide complex formation that accompanied DC maturation. These observations have important implications for the design of prophylactic and therapeutic DC vaccines and contribute to the understanding of the mechanisms causing immunosuppression during systemic blood infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978177      PMCID: PMC2077019          DOI: 10.1073/pnas.0708622104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Microbial and T cell-derived stimuli regulate antigen presentation by dendritic cells in vivo.

Authors:  S Manickasingham; C Reis e Sousa
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  MHC class II expression is regulated in dendritic cells independently of invariant chain degradation.

Authors:  J A Villadangos; M Cardoso; R J Steptoe; D van Berkel; J Pooley; F R Carbone; K Shortman
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

3.  Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis.

Authors:  Nicholas S Wilson; Dima El-Sukkari; José A Villadangos
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

4.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

5.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity.

Authors:  Andrea A Itano; Stephen J McSorley; R Lee Reinhardt; Benjamin D Ehst; Elizabeth Ingulli; Alexander Y Rudensky; Marc K Jenkins
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

Review 6.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

7.  Most lymphoid organ dendritic cell types are phenotypically and functionally immature.

Authors:  Nicholas S Wilson; Dima El-Sukkari; Gabrielle T Belz; Christopher M Smith; Raymond J Steptoe; William R Heath; Ken Shortman; José A Villadangos
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

8.  Dendritic cells process and present antigens across a range of maturation states.

Authors:  Ravi K Veeraswamy; Marina Cella; Marco Colonna; Emil R Unanue
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

9.  The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation.

Authors:  Dima El-Sukkari; Nicholas S Wilson; Katarina Hakansson; Raymond J Steptoe; Anders Grubb; Ken Shortman; José A Villadangos
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

10.  Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

Authors:  Aude Bonehill; Carlo Heirman; Sandra Tuyaerts; Annelies Michiels; Karine Breckpot; Francis Brasseur; Yi Zhang; Pierre Van Der Bruggen; Kris Thielemans
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

View more
  22 in total

Review 1.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

2.  Mature dendritic cells use endocytic receptors to capture and present antigens.

Authors:  Craig D Platt; Jessica K Ma; Cécile Chalouni; Melanie Ebersold; Hani Bou-Reslan; Richard A D Carano; Ira Mellman; Lélia Delamarre
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

3.  Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Authors:  Daimon P Simmons; Pamela A Wearsch; David H Canaday; Howard J Meyerson; Yi C Liu; Ying Wang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

Review 4.  Evasion of innate and adaptive immune responses by influenza A virus.

Authors:  Mirco Schmolke; Adolfo García-Sastre
Journal:  Cell Microbiol       Date:  2010-05-06       Impact factor: 3.715

5.  Antigen-specific regulation of IgE antibodies by non-antigen-specific γδ T cells.

Authors:  Yafei Huang; M Kemal Aydintug; Joshua Loomis; Megan K Macleod; Amy S McKee; Greg Kirchenbaum; Claudia V Jakubzick; Ross M Kedl; Deming Sun; Jordan Jacobelli; Rebecca L O'Brien; Willi K Born
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

Review 6.  The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.

Authors:  Bin Bao; Archana Thakur; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Shadan Ali; Lawrence G Lum; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2011-11-29

7.  Activation of Dendritic Cells Alters the Mechanism of MHC Class II Antigen Presentation to CD4 T Cells.

Authors:  Kyung-Jin Cho; Satoshi Ishido; Laurence C Eisenlohr; Paul A Roche
Journal:  J Immunol       Date:  2020-01-29       Impact factor: 5.422

8.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

9.  Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein activates dendritic cells and induces a Th1 polarization.

Authors:  Jun Sik Lee; Sung Jae Shin; Michael T Collins; In Duk Jung; Young-Il Jeong; Chang-Min Lee; Yong Kyoo Shin; Daejin Kim; Yeong-Min Park
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

10.  Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.

Authors:  D Neil Wedlock; Michel Denis; Gavin F Painter; Gary D Ainge; H Martin Vordermeier; R Glyn Hewinson; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2008-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.